PTSD is a prevalent condition for which veterans frequently seek treatment in the VA healthcare system. There are a number of first-line PTSD treatment approaches available, such as Prolonged Exposure and Cognitive Processing Therapy. However, the efficacy rates of these treatments is not as high as what has been observed with civilian populations and approximately 36% of individuals drop out of these treatments prematurely. A proposed alternative to these treatments is Written Exposure Therapy (WET), a brief, 5 session intervention that has been shown to reduce symptoms of PTSD and contribute to lower dropout rates. The goal of this study is to investigate whether WET is as effective compared to Prolonged Exposure (PE) in the treatment of PTSD in a sample of veterans diagnosed with PTSD. It will involve approximately 150 Veterans. This research is funded by the Department of Veterans Affairs.
Staff at sites who participate in the MUSC Women's Reproductive Behavioral Telehealth (WRBT) Program will be asked to participate in individual interviews or focus groups (group discussions) about their experience with the telemedicine program and fill out surveys. Patients in the WRBT Program will be asked to fill out surveys about their telemedicine experience.
The purpose of this study is to evaluate the effects of an FDA-approved medication called tolcapone in people who have both Alcohol Use Disorder (AUD) and Attention-Deficit/Hyperactivity Disorder (ADHD). The study involves seven visits over a three to four week period, including an assessment visit and two eight-day medication periods during which participants will be assigned to take, in a double-blinded fashion, both tolcapone and a placebo (three visits during each period). During two of these visits, participants will undergo a one-hour MRI scan. Participants must not be seeking treatment for AUD or ADHD and must not be currently taking any psychotropic medications, including stimulant medications for ADHD. Compensation is available for qualified participants.
This study will examine the effects of Epidiolex among adults who drink alcohol heavily but who are not seeking treatment for their alcohol use. Epidiolex is an FDA-approved formulation of cannabidiol, the primary non-psychoactive constituent of cannabis. Participants in the study will be randomly assigned to take Epidiolex or placebo for 8 days. There are 3 study visits, including a day-long visit in the laboratory.
This purpose of this research study is to collect feedback from participants about a web-based program for opioid misuse and opioid use disorder. Participants will be asked to review web-based content and take part in focus groups (group discussions) and individual interviews to provide feedback on the content. The study team is looking for pregnant women or women who have been pregnant in the past 2 years who misuse opioids or have opioid use disorder, as well as obstetric providers who treat pregnant women with opioid misuse and opioid use disorder to participate.
Transcranial magnetic stimulation (TMS), a non-invasive form of brain stimulation, produces lasting changes in the brain to treat depression and other brain disorders. Emphasis on clinical indications and efficacy has far outpaced a mechanistic understanding of how these changes are produced. In this study, we propose use of the pharmacologic agents d-cycloserine, demonstrated to be safe for human use, to probe in the molecular mechanism of long-term potentiation, the cellular basis of learning and memory. We will measure whether this agent can respectively strengthen the potentiation produced by TMS by looking at the amplitude of motor response (called motor evoked potential or MEP) of the thumb (through electromyography, or EMG).
A better understanding of its mechanism of action promises to optimize our ability to use TMS, and potentially improve duration and degree of response.
The purpose of this study is to better understand the different ways that female Veterans are affected by their experience with military sexual trauma (MST) and to look at the role of several factors that cause some people, but not others, to develop posttraumatic stress disorder (PTSD) or PTSD symptoms. This study is being conducted at the Charleston VA Medical Center, Tuscaloosa VA Medical Center and Atlanta VA Healthcare System. It will involve approximately 150 female Veterans who have experienced MST.
This study will examine the efficacy of intranasal oxytocin versus placebo in combination with Alcohol Behavioral Couples Therapy (ABCT) to reduce alcohol use disorder severity. We will also use observational coding and neuroimaging to examine behavioral and neural mechanisms underlying treatment outcomes.
Candidates for this study may or may not report disturbances in odor perception as their primary reason for seeking treatment at MUSC. This study is designed to collect long term, observational data from patients who are being treated with routine clinical care in health clinics at MUSC. Data from clinical questionnaires will be de-identified and stored in a database.
The purpose of this study is to determine if the medication lofexidine, taken together with buprenorphine or methadone, is more effective at reducing opioid craving, use and stress response than buprenorphine or methadone alone, and to see if this effect is different for men and women. Participants are randomly assigned to add either lofexidine or placebo to their buprenorphine or methadone treatment for five weeks. They return at the end of five weeks to participate in an opioid imagery task and stress task. Throughout the study, participants complete "CREMA" sessions (Cue Reactivity Ecologic Momentary Assessment) using an iPhone app three times a day. These sessions include looking at stressful and neutral pictures and rating stress and craving.